Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Conant Optical CoHKSE:02276 -5.46%78 ROE % is 21.78% as of Dec. 2025, which is 20% below its 10-year median of 27.25. GuruFocus rates HKSE:02276 with a GF Score™ of 78/100 and a GF Value™ of HK$15.68 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 798 Medical Devices & Instruments companies, Shanghai Conant Optical Co ranks better than 94.49% on this metric.
The historical rank and industry rank for Shanghai Conant Optical Co's ROE % or its related term are showing as below:
HKSE:02276'
s ROE % Range Over the Past 10 Years
Min: 19.46 Med: 27.25 Max: 69.34
Current: 19.46
During the past 8 years, Shanghai Conant Optical Co's highest ROE % was 69.34%. The lowest was 19.46%. And the median was 27.25%.
HKSE:02276's ROE % is ranked better than 94.49% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.715
vs HKSE:02276: 19.46
Shanghai Conant Optical Co (HKSE:02276) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Shanghai Conant Optical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Conant Optical Co ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shanghai Conant Optical Co's ROE % distribution charts can be found below:
* The bar in red indicates where Shanghai Conant Optical Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Shanghai Conant Optical Co (HKSE:02276) has a ROE % of 21.78% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai Conant Optical Co and its competitors. This is 20% below median its historical median of 27.25. Over the past decade, Shanghai Conant Optical Co's ROE % has ranged from 19.46 to 69.34. According to the industry distribution chart, Shanghai Conant Optical Co ranks #44 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 5.5%.
Is Shanghai Conant Optical Co's ROE % too high?
Shanghai Conant Optical Co's current ROE % of 21.78% is 20% below median its 10-year median of 27.25. Over the past 10 years, this metric has ranged from a low of 19.46 to a high of 69.34. The Medical Devices & Instruments industry median ROE % is 2.72. Shanghai Conant Optical Co's value of 21.78% is 702.2% above this industry median. Based on the distribution chart, Shanghai Conant Optical Co ranks #44 out of 798 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Conant Optical Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Conant Optical Co's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shanghai Conant Optical Co ranks #44 out of 798 companies for ROE %. This places Shanghai Conant Optical Co in the top 6% of its industry — outperforming the majority of peers. The industry median ROE % is 2.72. Shanghai Conant Optical Co's value of 21.78% is 702.2% above this benchmark. Historically, Shanghai Conant Optical Co's own ROE % has ranged from 19.46 to 69.34 over the past decade. While the company's 10-year median is 27.25 vs. the industry median of 2.72, Shanghai Conant Optical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.72, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Conant Optical Co's current ROE % of 21.78% is 702.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Shanghai Conant Optical Co and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Conant Optical Co's current ROE % is 21.78%, which is 20% below median its own 10-year median of 27.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Conant Optical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Conant Optical Co (HKSE:02276) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$15.68, compared to a current price of HK$38.44 — trading 145.2% above its estimated fair value. The current ROE % is 21.78%, which is 20% below median its 10-year median of 27.25 and 702.2% above the Medical Devices & Instruments industry median of 2.72. Shanghai Conant Optical Co's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Shanghai Conant Optical Co (HKSE:02276), the current ROE % is 21.78% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Conant Optical Co (HKSE:02276) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Conant Optical Co stock appears to be overvalued.
The current stock price of HK$38.44 is trading 145.2% above its estimated GF Value™ of HK$15.68.
GuruFocus considers Shanghai Conant Optical Co to be Significantly Overvalued.
Key valuation signals for HKSE:02276:
ROE %: 21.78% (20% below median its 10-year median of 27.25)
GF Value™: HK$15.68 vs. price of HK$38.44 (145.2% above fair value)
Industry Position: 702.2% above the Medical Devices & Instruments median (#44 of 798)
No single metric tells the full story. See the HKSE:02276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressNo. 1-42, Lane 83, Hongxiang North Road, 4th Floor, Building 35, Lin-gang Special Area, China (Shanghai) Pilot Free Trade Zone China, Shanghai, CHN
Shanghai Conant Optical Co Ltd is a resin spectacle lens manufacturer in China. The company offers a wide range of resin spectacle lenses to its customers including standardized lenses and customized lenses. The spectacle lenses are also tinted, coated, or cast with various films or coatings for added functionality, such as polarised, photochromic, blue-ray blocking, anti-scratch, anti-reflection, and anti-smudge. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the Americas, Europe, Oceania, Africa, and Asia (except for mainland China). It products include: CR-Freeform; CoMax; AC lens; Gaming Glassed, Antifog Lens; MyoEase; Polycarbonate lens; Photochromic coating lens; SingleVision Finished Lens; and Others.
78GF Score
Get the complete analysis for HKSE:02276
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02276 has been successfully added to your 
